In conclusion, our systematic investigation revealed the detailed molecular mechanism underlying cordycepin-induced JNK signaling activation through inhibition of c-FLIPL expression, and demonstrates the potential of cordycepin as a therapeutic agent for renal cancer treatment. Here, CFLAR is linked to renal carcinoma.